| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
NEWS |
Taming a Mutinous Mutant: An Errant Receptor Becomes a Prime Cancer Target
| The first 10% of the full text of this article appears below. |
Vaccines typically are given to prevent disease, but in theory there's no reason they couldn’t be used to nudge the immune system into fighting a disease someone already has. In practice, it's a different story. Researchers have been trying for years to come up with therapeutic vaccines to fight established cancer and other diseases, with little success.
Now a vaccine for a nasty brain cancer is showing early promise. It will soon be tested in a multicenter phase II trial just getting under way for patients with glioblastoma, the most common adult brain cancer, and it may eventually see duty in other cancer types.
About 10,000 patients will be diagnosed with glioblastoma this year in the United States; only about half of them will survive 1 year. A
Discovering Mutant EGFR
Outside the Brain
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Yoshimoto, J. Dang, S. Zhu, D. Nathanson, T. Huang, R. Dumont, D. B. Seligson, W. H. Yong, Z. Xiong, N. Rao, et al. Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples Clin. Cancer Res., January 15, 2008; 14(2): 488 - 493. [Abstract] [Full Text] [PDF]
|
|